文献速递放疗物理与技术姑息放疗与转移瘤

从阿尔法到奥密克戎:某放射肿瘤学网络基于生物隔离的COVID-19经验

From Alpha to Omicron: A Radiation Oncology Network's Biocontainment-Based COVID-19 Experience.
PubMed 文献 · Adv Radiat Oncol · 2022-10-25

为给需放疗的COVID-19急症患者提供最安全环境,该研究在CT模拟机室和光子及质子治疗室加装高效空气过滤系统建成负压环境,并实施无症状筛查、延迟和治疗方案。2020年6月至2022年1月5个中心共治疗6525例患者,42例COVID-19患者在高风险不能延迟时按生物隔离方案治疗,其中61.9%避免了治疗中断,64.3%为根治性 intent,每例中位生物隔离治疗6次(范围1-15)。

要点

  • 在CT模拟机室和光子及质子治疗室加装高效空气过滤系统可建成负压生物隔离环境。
  • 2020年6月至2022年1月5个中心共治疗6525例患者,其中42例COVID-19患者按生物隔离方案治疗。
  • 61.9%的COVID-19患者通过安全措施避免了治疗期间长时间中断,64.3%为根治性治疗。

核心结论

  • 建设负压环境和制定COVID-19生物隔离治疗方案使本科室能够安全治疗COVID-19急症放射肿瘤患者,并增强了未来生物防备能力。
  • 这些生物隔离单元在当前或未来任何传染病暴发期间为放射肿瘤学设定了高安全标准。

研究设计与样本

  • 回顾性分析2020年6月至2022年1月按COVID-19方案治疗的患者,并描述CT模拟机室和光子及质子治疗室负压改造、筛查、延迟和治疗方案。

主要发现

  • 2020年6月至2022年1月5个独立中心共治疗6525例患者。
  • 42例若放疗延迟则不良结局风险最高的COVID-19患者按生物隔离方案治疗,而其他患者则被安排治疗暂停。
  • 61.9%的患者通过安全措施避免了治疗期间长时间中断。
  • 64.3%的患者接受根治性 intent 治疗。
  • 每例患者清除COVID-19并恢复常规气流环境治疗前所需生物隔离治疗次数的中位数为6次(范围1-15)。

关键数值与推荐

  • 无症状COVID-19筛查方案实施于所有患者开始治疗前。
  • 患者可根据预定义优先等级和方案在生物隔离环境中进行模拟和/或治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To develop the safest possible environment for treating urgent patients with COVID-19 requiring radiation, we describe the unique construction of negative air pressure computed tomography simulator and linear accelerator treatment vaults in addition to screening, delay, and treatment protocols and their evolution over the course of the COVID-19 pandemic. METHODS AND MATERIALS: Construction of large high-efficiency particulate air filter air-flow systems into existing ductwork in computed tomography simulator rooms and photon and proton treatment vaults was completed to create negative-pressure rooms. An asymptomatic COVID-19 screening protocol was implemented for all patients before initiation of treatment. Patients could undergo simulation and/or treatment in the biocontainment environments according to a predefined priority scale and protocol. Patients treated under the COVID-19 protocol from June 2020 to January 2022 were retrospectively reviewed. RESULTS: Negative air-flow environments were created across a regional network, including a multi-gantry proton therapy unit. In total, 6525 patients were treated from June 2020 through January 2022 across 5 separate centers. The majority of patients with COVID-19 had radiation treatment deferred when deemed safe. A total of 42 patients with COVID-19, who were at highest risk of an adverse outcome should there be a radiation delay, were treated under the COVID-19 biocontainment protocol in contrast to those who were placed on treatment break. For 61.9% of patients, these safety measures mitigated an extended break during treatment. The majority of patients (64.3%) were treated with curative intent. The median number of biocontainment sessions required by each patient was 6 (range, 1-15) before COVID-19 clearance and resumption of treatment in a normal air-flow environment. CONCLUSIONS: Constructing negative-pressure environments and developing a COVID-19 biocontainment treatment protocol allowed for the safe treatment of urgent radiation oncology patients with COVID-19 within our department and strengthens future biopreparedness. These biocontainment units set a high standard of safety in radiation oncology during the current or for any future infectious outbreak.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Cao Y, Fabre V, Anderson R, et al. From Alpha to Omicron: A Radiation Oncology Network's Biocontainment-Based COVID-19 Experience. Adv Radiat Oncol. 2022. PMID: 36311821. doi:10.1016/j.adro.2022.101094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。